NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE
    71.
    发明申请
    NOVEL N-OXIDES OF FURANYL-OXADIAZOLYL-DIAZABICYCLONONANE DERIVATIVES AND THEIR MEDICAL USE 审中-公开
    新戊氧基 - 二氮杂双环十二烷衍生物的新型N-氧化物及其医药用途

    公开(公告)号:US20110319397A1

    公开(公告)日:2011-12-29

    申请号:US13145998

    申请日:2010-01-25

    CPC分类号: C07D471/08

    摘要: This invention relates to novel N-oxides of certain furanyl-oxadiazolyl-diazabicyclononane derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters.Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译: 本发明涉及某些呋喃基 - 恶二唑基 - 二氮杂双环壬烷衍生物的新N-氧化物及其在制备药物组合物中的用途。 发现本发明的化合物是烟碱乙酰胆碱受体的胆碱能配体和单胺受体和转运蛋白的调节剂。 由于其药理学特征,本发明的化合物可用于治疗与中枢神经系统(CNS),周围神经系统(PNS),疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩,内分泌疾病或病症,与神经变性相关的疾病或病症,与由化学物质的滥用终止引起的炎症,疼痛和戒断症状相关的疾病或病症。

    TREATMENT OF ANXIETY DISORDERS
    73.
    发明申请
    TREATMENT OF ANXIETY DISORDERS 审中-公开
    治疗恶心病

    公开(公告)号:US20110207722A1

    公开(公告)日:2011-08-25

    申请号:US13059807

    申请日:2009-08-19

    摘要: This invention relates to the treatment of anxiety disorders. The invention furthermore relates to novel pharmaceutical compositions comprising a therapeutically effective amount of the compound exo-7-(8-H-8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one, or a therapeutically effective amount of the compound exo- 7-(8-H-8- aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one and a benzodiazepine drug.

    摘要翻译: 本发明涉及焦虑症的治疗。 本发明还涉及新的药物组合物,其包含治疗有效量的化合物外-7-(8-H-8-氮杂 - 双环[3.2.1]辛-3-基氧基) - 苯并二氢吡喃-2-酮或 化合物外-7-(8-H-8-氮杂 - 双环[3.2.1]辛-3-基氧基) - 苯并二氢吡喃-2-酮和苯并二氮杂药物的治疗有效量。

    1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands
    78.
    发明授权
    1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives useful as nicotinic acetylcholine receptor ligands 失效
    可用作烟碱乙酰胆碱受体配体的1,4-二氮杂双环[3.2.2]壬基杂芳基衍生物

    公开(公告)号:US07935695B2

    公开(公告)日:2011-05-03

    申请号:US12733168

    申请日:2008-08-14

    CPC分类号: C07D471/08

    摘要: This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl heteroaryl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be cholinergic ligands at the nicotinic acetylcholine receptors.Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

    摘要翻译: 本发明涉及新的1,4-二氮杂 - 双环[3.2.2]壬基杂芳基衍生物及其在制备药物组合物中的用途。 发现本发明的化合物是烟碱乙酰胆碱受体的胆碱能配体。 由于其药理学特征,本发明的化合物可用于治疗与中枢神经系统(CNS),周围神经系统(PNS),疾病或病症相关的胆碱能系统相关的疾病或障碍 平滑肌肉收缩,内分泌疾病或病症,与神经变性相关的疾病或病症,与由化学物质的滥用终止引起的炎症,疼痛和戒断症状相关的疾病或病症。